Senti Biosciences shares jumped over 20% in premarket trading after the FDA granted RMAT status to its immune-cell therapy, SENTI-202, enabling accelerated review. This marks the treatment second FDA designation this year. Retail sentiment on Stocktwits spiked to extremely bullish, with message volume also hitting extremely high levels.